KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Long-Term Debt Repayments (2016 - 2025)

Eli Lilly's Long-Term Debt Repayments history spans 16 years, with the latest figure at -$100000.0 for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments rose 50.0% year-over-year to -$100000.0; the TTM value through Dec 2025 reached -$300000.0, down 50.0%, while the annual FY2025 figure was $778.0 million, 17.17% up from the prior year.
  • Long-Term Debt Repayments reached -$100000.0 in Q4 2025 per LLY's latest filing, up from -$200000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $1.9 billion in Q3 2021 to a low of -$200000.0 in Q4 2024.
  • Average Long-Term Debt Repayments over 4 years is $577.5 million, with a median of $355.1 million recorded in 2021.
  • Peak YoY movement for Long-Term Debt Repayments: tumbled 50.0% in 2021, then surged 50.0% in 2025.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $100000.0 in 2021, then soared by 849800.0% to $849.9 million in 2022, then plummeted by 100.02% to -$200000.0 in 2024, then soared by 50.0% to -$100000.0 in 2025.
  • Per Business Quant, the three most recent readings for LLY's Long-Term Debt Repayments are -$100000.0 (Q4 2025), -$200000.0 (Q4 2024), and $849.9 million (Q2 2022).